IRE1α Small Molecule Inhibitors for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aggressive tumors have developed strategies to thrive under adverse conditions, such as hypoxia, nutrient starvation, and oxidative stress, making it challenging to effectively target cancer cells using existing methods.
Innovation Solution
Development of compounds that selectively bind to IRE1α, a protein involved in the endoplasmic reticulum stress response pathway, blocking its dimerization, auto-transphosphorylation, and kinase activity, thereby inhibiting the survival mechanisms of cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing methods are used to target cancer cells, then treatment approaches are limited, but aggressive tumors have evolved survival strategies that make them resistant to conventional therapies
Solution Approach 1:
The patent employs small molecule compounds that bind to specific residues (Thr899, Ser900, Thr901, Ser902, or Thr903) in the IRE1α protein to modulate its conformational state and activity. By changing the molecular parameters of IRE1α through selective residue binding, the compounds alter the protein's functional state, thereby affecting cancer cell survival mechanisms under adverse conditions such as hypoxia and nutrient starvation.
2Productivity
If IRE1α activity is blocked to inhibit cancer cell survival, then aggressive tumor growth is targeted, but normal cellular stress response mechanisms may be affected
Solution Approach 1:
The patent achieves selective inhibition by targeting specific local regions (residues Thr899, Ser900, Thr901, Ser902, or Thr903) within the IRE1α protein structure. This localized binding approach allows the compounds to modulate IRE1α activity in a site-specific manner, potentially distinguishing between pathological and physiological functions of the protein while inhibiting cancer cell survival mechanisms.
Solution Approach 2:
The compounds perform partial inhibition of IRE1α activity by binding to specific residues without completely abolishing protein function. This partial action allows sufficient modulation to inhibit cancer cell proliferation under stress conditions while potentially preserving essential cellular stress response mechanisms needed for normal cell function.
Data Source
AI summary
Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.